Elizabeth A. Guancial

3.5k total citations · 1 hit paper
49 papers, 1.6k citations indexed

About

Elizabeth A. Guancial is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Elizabeth A. Guancial has authored 49 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Surgery, 17 papers in Pulmonary and Respiratory Medicine and 14 papers in Oncology. Recurrent topics in Elizabeth A. Guancial's work include Bladder and Urothelial Cancer Treatments (24 papers), Urinary and Genital Oncology Studies (12 papers) and Prostate Cancer Treatment and Research (7 papers). Elizabeth A. Guancial is often cited by papers focused on Bladder and Urothelial Cancer Treatments (24 papers), Urinary and Genital Oncology Studies (12 papers) and Prostate Cancer Treatment and Research (7 papers). Elizabeth A. Guancial collaborates with scholars based in United States, Greece and Canada. Elizabeth A. Guancial's co-authors include Elaine M. Hylek, Reshma Jagsi, Yuchiao Chang, Nancy J. Tarbell, Rebecca Starr, Lori Henault, Edward M. Messing, Shuyuan Yeh, Jonathan E. Rosenberg and Joaquim Bellmunt and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Elizabeth A. Guancial

46 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The “Gender Gap” in Authorship of Academic Medical Literature — A 35-Year Perspective

2006 653 citations Elizabeth A. Guancial et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elizabeth A. Guancial United States	18	584	554	422	412	273	49	1.6k
Amelia Grover United States	18	412 0.7×	371 0.7×	160 0.4×	238 0.6×	462 1.7×	28	1.4k
Elizabeth H. Stephens United States	23	422 0.7×	278 0.5×	564 1.3×	197 0.5×	116 0.4×	144	1.7k
Valentine Nfonsam United States	22	325 0.6×	337 0.6×	362 0.9×	117 0.3×	437 1.6×	78	1.4k
Nita Ahuja United States	16	273 0.5×	299 0.5×	480 1.1×	181 0.4×	633 2.3×	42	1.3k
Sarah M. Temkin United States	31	260 0.4×	351 0.6×	376 0.9×	719 1.7×	868 3.2×	131	3.0k
Ariela L. Marshall United States	20	245 0.4×	297 0.5×	121 0.3×	129 0.3×	161 0.6×	90	1.3k
Vivian W. Pinn United States	21	258 0.4×	416 0.8×	214 0.5×	155 0.4×	195 0.7×	64	1.7k
Maureen D. Moore United States	18	197 0.3×	169 0.3×	292 0.7×	177 0.4×	185 0.7×	39	929
Michail Sideris United Kingdom	19	110 0.2×	452 0.8×	351 0.8×	119 0.3×	353 1.3×	86	1.5k
Quyen D. Chu United States	25	135 0.2×	291 0.5×	648 1.5×	350 0.8×	1.0k 3.8×	134	2.4k

Countries citing papers authored by Elizabeth A. Guancial

Since Specialization

Citations

This map shows the geographic impact of Elizabeth A. Guancial's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth A. Guancial with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth A. Guancial more than expected).

Fields of papers citing papers by Elizabeth A. Guancial

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth A. Guancial. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth A. Guancial. The network helps show where Elizabeth A. Guancial may publish in the future.

Co-authorship network of co-authors of Elizabeth A. Guancial

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth A. Guancial. A scholar is included among the top collaborators of Elizabeth A. Guancial based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth A. Guancial. Elizabeth A. Guancial is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Aggen, David H., Meredith McKean, Jean Hoffman‐Censits, et al.. (2024). IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.. Journal of Clinical Oncology. 42(16_suppl). 2599–2599.

Aggen, David H., Meredith McKean, Nehal J. Lakhani, et al.. (2022). 661 Initial results from a phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma. Regular and Young Investigator Award Abstracts. A692–A692. 3 indexed citations

McKean, Meredith, David H. Aggen, Nehal J. Lakhani, et al.. (2022). Phase 1a/b open-label study of IK-175, an oral AHR inhibitor, alone and in combination with nivolumab in patients with locally advanced or metastatic solid tumors and urothelial carcinoma.. Journal of Clinical Oncology. 40(16_suppl). TPS3169–TPS3169. 8 indexed citations

Kilari, Deepak, Jason Zittel, Arpan Patel, et al.. (2020). 677P A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis. Annals of Oncology. 31. S540–S541. 1 indexed citations

Grivas, Petros, Amir Mortazavi, Joel Picus, et al.. (2018). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 125(4). 533–540. 36 indexed citations

Pandya, Chintan, et al.. (2018). Using electronic medical record system to improve compliance with national guidelines for comprehensive distress screening in cancer patients.. Journal of Clinical Oncology. 36(30_suppl). 309–309. 1 indexed citations

Duberstein, Paul R., Michael Chen, Benjamin P. Chapman, et al.. (2017). Fatalism and educational disparities in beliefs about the curability of advanced cancer. Patient Education and Counseling. 101(1). 113–118. 29 indexed citations

Loh, Kah Poh, et al.. (2016). Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma. Clinical Genitourinary Cancer. 14(4). e449–e452. 13 indexed citations

Flynn, Timothy C., et al.. (2016). Case Report: Spironolactone Withdrawal Associated With a Dramatic Response in a Patient With Metastatic Castrate-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 15(1). e95–e97. 9 indexed citations

10.

Meng, Yifan, et al.. (2016). Complete Remission of Locally Advanced Penile Squamous Cell Carcinoma after Multimodality Treatment. Rare Tumors. 8(4). 191–193. 1 indexed citations

11.

Guancial, Elizabeth A. & Jonathan E. Rosenberg. (2015). The Role of Genomics in the Management of Advanced Bladder Cancer. Current Treatment Options in Oncology. 16(1). 319–319. 10 indexed citations

12.

Mullane, Stephanie A., Lillian Werner, Elizabeth A. Guancial, et al.. (2015). Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 14(4). 352–359. 31 indexed citations

13.

Guancial, Elizabeth A., Deepak Kilari, Edward M. Messing, & Eric S. Kim. (2015). Platinum concentration in bladder tissue treated with neoadjuvant chemotherapy and pathologic response.. Journal of Clinical Oncology. 33(7_suppl). 341–341. 2 indexed citations

14.

Fung, Chunkit, Elizabeth A. Guancial, Breton Roussel, et al.. (2015). Bladder cancer in the elderly patient: challenges and solutions. Clinical Interventions in Aging. 10. 939–939. 56 indexed citations

15.

Fung, Chunkit, Chintan Pandya, Elizabeth A. Guancial, et al.. (2014). Impact of Bladder Cancer on Health Related Quality of Life in 1,476 Older Americans: A Cross-Sectional Study. The Journal of Urology. 192(3). 690–695. 40 indexed citations

16.

Guancial, Elizabeth A., Joaquim Bellmunt, Shuyuan Yeh, Jonathan E. Rosenberg, & David M. Berman. (2013). The evolving understanding of microRNA in bladder cancer. Urologic Oncology Seminars and Original Investigations. 32(1). 41.e31–41.e40. 72 indexed citations

17.

Werner, Lillian, Shamini Selvarajah, Barbara A. Weir, et al.. (2011). Identification of a novel urothelial carcinoma (UC) biomarker of lethality.. Journal of Clinical Oncology. 29(15_suppl). 4569–4569. 2 indexed citations

18.

Guancial, Elizabeth A. & Mary‐Ellen Taplin. (2011). Case Report: Responses to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer After Extensive Docetaxel Treatment. Clinical Genitourinary Cancer. 9(2). 130–132.

19.

Kassis, Jareer, Victoria M. Virador, Elizabeth A. Guancial, et al.. (2009). Genomic and phenotypic analysis reveals a key role for CCN1 (CYR61) in BAG3—modulated adhesion and invasion. The Journal of Pathology. 218(4). 495–504. 23 indexed citations

20.

Kassis, Jareer, Elizabeth A. Guancial, Howard Doong, Victoria M. Virador, & Elise C. Kohn. (2006). CAIR-1/BAG-3 modulates cell adhesion and migration by downregulating activity of focal adhesion proteins. Experimental Cell Research. 312(15). 2962–2971. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact